Apotex Inc. entered into Asset Purchase Agreement to acquire Certain assets related to certain pharmaceutical products of Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) for $100 million on April 22, 2026. A cash consideration of $100 million will be paid by Apotex Inc. As part of consideration, $100 million is paid towards assets of Certain assets related to certain pharmaceutical products of Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc. must pay a termination fee of $4 million to Apotex Inc. If Apotex fails to consummate the closing of the Transaction and the Company stood ready, willing, and able to consummate the closing, then Apotex must pay a reverse termination fee of $4,000,000 to the Cumberland Pharmaceuticals Inc.

The transaction is subject to the approval of Cumberland board and shareholders, and regulatory approvals. The Transaction has been unanimously approved by the board of directors.

Raymond James Financial, Inc. acted as financial advisor for Apotex Inc. VelocityHealth Securities, Inc. acted as a fairness opinion provider and financial advisor to Apotex Inc.The team of Kirkland & Ellis LLP led by Ngozi Nezianya, Matt Arenson and Aaron Lorber, Matt Darch, acted as legal advisor for Apotex Inc. The team of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC led by Tonya Mitchem Grindon, Nathan Kibler and Charles W. Goldberg Jr. acted as legal advisor for Cumberland Pharmaceuticals Inc.